This trial has been completed.

Condition traumatic brain injury
Treatments computerized plasticity-based adaptive cognitive training, commercially available computerized training
Sponsor Posit Science Corporation
Collaborator Congressionally Directed Medical Research Programs
Start date September 2013
End date March 2017
Trial size 86 participants
Trial identifier NCT01640158, BPI-1002-11


The primary objective of this study is to evaluate the effects of plasticity-based, adaptive cognitive remediation on the cognitive abilities, functional status and quality of life of soldiers and veterans diagnosed with persistent post-concussive symptoms (PPCS) following a mild traumatic brain injury (mTBI, also referred to as a concussion, or blast exposure), as compared to a computer-based control.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Primary purpose treatment
Masking participant, care provider, investigator, outcomes assessor
Computerized plasticity-based adaptive cognitive training, up to 65 hours
computerized plasticity-based adaptive cognitive training
Computerized plasticity-based adaptive cognitive training, up to 65 hours
(Active Comparator)
Commercially available computerized training, up to 65 hours
commercially available computerized training
Commercially available computerized training, up to 65 hours

Primary Outcomes

Verbal Learning and Memory
time frame: 6 months post

Secondary Outcomes

Executive Function
time frame: 6 Months

Eligibility Criteria

All participants from 18 years up to 50 years old.

Inclusion Criteria: 1. Subjects must be 18 - 50 years of age at the time of consent 2. Subjects must have a diagnosis of mTBI 3. Subjects must have persistent cognitive dysfunction confirmed by an objective measure (as recommended by the ICD-10 definition for post-concussion syndrome) or a subjective measure (as recommended by the DSV-IV definition of post-concussional disorder). 4. Subjects must be at least three months out from their most recent TBI, concussion, and/or blast exposure to minimize the effects of spontaneous recovery, as verified through participant interview. 5. Subjects must be fluent English speakers. 6. Subjects must have adequate sensorimotor capacity to perform the program in the judgment of the consenting clinician. Exclusion Criteria: 1. Subjects must not have a history of penetrating head wounds or a diagnosis of moderate or severe TBI. 2. Subjects must not be in-patients. 3. Subjects must not have a diagnosis of an illness or condition with known cognitive consequences (e.g., schizophrenia, bipolar disorder, cancer, multiple sclerosis). 4. Subjects must not show suicidal ideation as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS). 5. Subjects must now show signs of intoxication due to current substance abuse (including alcohol and/or illegal drugs) during any in person visit. 6. Subjects must not have clinically significant visual field deficits noted by the consenting staff member by direct observation or by medical history. 7. Subjects must not be judged to be lacking effort. 8. Subjects must not have problems performing assessments or comprehending or following spoken instructions. 9. Subjects must not be enrolled in a concurrent clinical trial involving an investigational pharmaceutical, nutraceutical, medical device, or behavioral treatment for TBI that could affect the outcome of this study.

Additional Information

Official title BRAVE Trial: Broad-spectrum Cognitive Remediation Available to Veterans: Effects of a Brain Plasticity-based Program in Mild Traumatic Brain Injury (mTBI)
Principal investigator Henry W Mahncke, PhD
Description This study is a multi-site, prospective, parallel arm, double-blind, randomized, controlled clinical trial to assess the safety and efficacy of plasticity-based, adaptive, computerized cognitive remediation treatment versus a computer-based control. Both the study and the cognitive remediation treatments meet the criteria of Non-Significant Risk.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Posit Science Corporation.